Loading patent…
AssigneeSorrento Therapeutics, Inc.
InventorsHeyue Zhou, Xia Cao, Lucy Lu, Ying Yan, Yanliang Zhang, Henry Hongjun Ji, Robert Allen
Estimating the term…
The present disclosure provides antigen-binding proteins, such as fully human antibodies, that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus and uses thereof. In various embodiments, the anti-spike protein antibodies are neutralizing antibodies that prevent binding of the SARS-CoV-2 coronavirus to a target cell expressing the ACE2 protein. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Also provided herein are nucleic acids and recombinant expression vectors that encode the anti-spike protein antibodies and antibody fragments disclosed herein and transgenic cells transected with such nucleic acids and expression vectors. Further provided are methods for preparing and using such anti-spike protein antibodies. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein.
An isolated antigen-binding protein that specifically binds the spike (S) protein of SARS-CoV-2, wherein the antigen-binding protein comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7.
An isolated antigen-binding protein that specifically binds the S protein of SARS-CoV-2, comprising a heavy chain variable region comprising a heavy chain complementarity determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:8, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:9, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:10, and a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO:11, a light chain CDR2 having the amino acid sequence of SEQ ID NO:12, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:13.
The isolated antigen-binding protein of any one of the preceding claims, wherein the antigen-binding protein is a neutralizing antibody or antigen-binding fragment thereof that blocks binding of the SARS-CoV-2 S protein to the ACE2 protein.
The isolated antigen-binding protein of any one of the preceding claims, wherein the antigen-binding protein is a neutralizing antibody or antigen-binding fragment thereof that blocks SARS-CoV-2 infection of target cells.
A pharmaceutical composition, comprising the antigen-binding protein of any one of the preceding claims and a pharmaceutically-acceptable excipient.
A nucleic acid molecule that comprises a nucleic acid sequence encoding a polypeptide comprising a heavy chain variable region having at least 95% identity to SEQ ID NO:6.
A nucleic acid molecule that comprises a nucleic acid sequence encoding a polypeptide comprising a light chain variable region having at least 95% identity to SEQ ID NO:7.
A vector comprising a nucleic acid sequence encoding a heavy chain variable region having at least 95% identity to SEQ ID NO:6 and a nucleic acid sequence encoding a light chain variable region having at least 95% identity to SEQ ID NO:7.
Dependencies are inferred from the claim text.